Home Alzheimer’s Disease Strategies Combining Nivolumab Show Promise for Classic Hodgkin Lymphoma

Strategies Combining Nivolumab Show Promise for Classic Hodgkin Lymphoma

In a study of 2 experimental, nivolumab (Opdivo)-based, first-line treatment strategies in patients with early-stage unfavorable classic Hodgkin lymphoma, published in JAMA Oncology, researchers found that both strategies combining nivolumab and doxorubicin (Adriamycin), vinblastine (Velban), and dacarbazine (AVD) were feasible, highly effective, and resulted in excellent 12-month progression-free survival (PFS), they wrote.

“We observed early and sustained responses in both treatment groups and an unexpectedly high interim CR rate even after 4 doses of nivolumab alone,” the authors wrote. “Anti-PD-1-based first-line treatment of early-stage (classic Hodgkin lymphoma) warrants further evaluation within future trials, comparing a fully concomitant treatment with standard of care or an individualized approach with sequential anti-PD-1 treatment guided, e.g., by interim…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments